Hisamitsu Pharmaceutical : Notice Regarding Status of Acquisition of Treasury Shares
September 03, 2023
Share
This material is an English translation of the press release announced on Sep. 4, 2023 in Japanese, and the Japanese release is given priority about the content and the interpretation.
Sep. 4, 2023
Notice Regarding Status of Acquisition of Treasury Shares
(Acquisition of treasury shares in accordance with the provisions of the Articles of Incorporation pursuant to
Article 165, paragraph 2 of the Companies Act)
Hisamitsu Pharmaceutical Co., Inc. (Head office: Tosu City, Saga Prefecture; President and CEO: NAKATOMI, Kazuhide) hereby announces the status (in progress) of acquisition of treasury shares in accordance with Article 156 of the Companies Act as applied pursuant to Article 165, paragraph 3 of the same Act, as announced on July 13, 2023, as follows.
1.
Type of shares acquired Common shares of the Company
2.
Total number of shares acquired
277,400 share
3.
Total amount of shares acquired
133,595,600 yen
4.
Period for acquisition
August 1, 2023 to August 31, 2023 (based on contract)
5.
Method of acquisition
Market purchase on the Tokyo Stock Exchange
(Reference)
Resolutions of the board of directors meeting held on July 13, 2023
Type of shares to be acquired: Common shares of the Company
Total number of shares that may be acquired: 2 million shares (maximum)
(Percentage of total number of shares outstanding (excluding treasury shares): 2.57%)
Total amount of shares acquired: 10 billion yen (maximum)
Period for acquisition: July 14, 2023 to February 29, 2024
Method of acquisition: Market purchase on the Tokyo Stock Exchange
Cumulative total of treasury shares acquired based on the above resolutions of the board of directors meeting (as of July 31, 2023)
(1)
Total number of shares acquired
277,400 share
(2)
Total amount of shares acquired
1,333,595,600 yen
Attachments
Original Link
Original Document
Permalink
Disclaimer
Hisamitsu Pharmaceutical Co. Ltd. published this content on 04 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 September 2023 08:54:11 UTC.
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
HISAMITSU PHARMACEUTICAL CO., INC. 
